Mar 06, 2023 / 06:30PM GMT
Phil Nadeau - TD Cowen - Analyst
Welcome once again to TD Cowen's 43rd annual healthcare conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to do a fireside chat with Annexon. We have Doug Love, President and CEO of Annexon, with us this afternoon.
Questions and Answers:
Phil Nadeau - TD Cowen - AnalystDoug, in January Annexon announced plans to prioritize four programs. Could you briefly outline Annexon's overall strategy, the four programs that were prioritized and the rationale?
Doug Love - Annexon Inc. - President & CEO
Yeah, absolutely. So, as you all know, we're focused on the classical pathway in C1q, the initiator of the pathway. One of the things that's been quite unique in the complement space is its druggability. It's been really well validated clinically and now commercially in a host of different diseases in autoimmune and neurodegeneration.
Based on work we've done in an early set of our pipeline programs, we decided to focus on four key
Trustpilot
